Recruiting specialized omics professionals — those working in genomics, proteomics, spatial biology, single-cell, and NGS — is difficult for seven structural reasons: a small global talent pool, a rare hybrid skill set combining scientific depth with commercial fluency, demand outpacing supply, geographic concentration of talent, long candidate ramp times, fast-moving compensation benchmarks, and a tight community where employer reputation travels quickly. Each of these is explained in detail below.
Key takeaways
- Recruiting specialized omics professionals is difficult because the global talent pool is small, the required skill set is hybrid (deep science + commercial), and demand has grown faster than supply. The global genomics market alone is projected to grow from USD 47B in 2025 to USD 85B by 2030 (MarketsandMarkets, 2025) — but the commercial talent pipeline does not grow at that rate.
- Most viable candidates for senior roles (Field Application Scientist, Sales Specialist, Product Manager) number in the low thousands globally, not millions.
- The top 80% of qualified candidates are passive — not actively job-hunting — which means inbound applications surface a fraction of the real market.
- Geography concentrates the talent: in Europe, the DACH region, the UK Golden Triangle, and Benelux dominate; in the US, Boston, the Bay Area, San Diego, and Research Triangle.
- Companies relying on generic life-sciences salary surveys consistently underpay and lose finalists. Specialist omics recruitment partners exist because the standard hiring playbook does not work in this market.
Introduction
The -omics industry has produced some of the most transformative technologies of the last decade: single-cell sequencing, spatial transcriptomics, long-read genomics, and mass-spectrometry-based proteomics. Ask any commercial leader at a biotech scale-up where their real bottleneck is, and the answer rarely involves the technology. It’s the people — specifically, the commercial professionals who can sell, support, and scale that technology across regions.
This article explains why hiring omics talent breaks the assumptions of mainstream recruitment, and what works instead.
1. The omics talent pool is genuinely small
Commercial roles in -omics — Field Application Scientist (FAS), Sales Specialist, Product Manager, Sales Director — require something uncommon: deep scientific literacy combined with commercial instinct. A typical strong candidate has spent years in a wet lab (often through a PhD) before moving into a customer-facing role.
The number of people globally with five or more years of commercial experience in genomics, single-cell, spatial biology, proteomics, or NGS workflows is measured in the low thousands. When you narrow further — by territory, language, therapeutic focus, or platform experience (10x Genomics vs. Vizgen vs. Bruker vs. Oxford Nanopore) — the qualified pool for a single role often shrinks to a few dozen people worldwide.
2. The required skill set is hybrid — and you can’t fake either side
Traditional sales recruiters find sellers. Traditional scientific recruiters find scientists. Omics roles require both, in one person:
- A Field Application Scientist troubleshoots a failed Visium run in the morning and presents ROI to a procurement committee in the afternoon.
- A Sales Specialist discusses alignment algorithms with a bioinformatics core director and negotiates a six-figure capital purchase in the same conversation.
- A Product Manager interprets customer feedback through both a technical lens and a revenue lens.
Candidates who lean too heavily in one direction — strong scientist but weak commercial, or strong seller but weak science — tend to underperform in the first 12 months and churn. The financial impact of that mismatch is the subject of our separate article on the true cost of a bad commercial hire in biotech.
3. Demand has grown faster than the talent supply
According to MarketsandMarkets, the global genomics market is projected to grow from USD 47.07 billion in 2025 to USD 85.09 billion by 2030 — a CAGR of 12.6%. Spatial biology alone went from two serious players in 2018 to more than a dozen by 2024. Long-read sequencing matured. Single-cell became standard. Multi-omics platforms emerged. Each new platform needs its own commercial team in every major region.
But scientists do not transition into commercial roles overnight. The “PhD-to-sales” talent pipeline moves on a 5–10 year cadence, not 1–2. Companies end up competing for the same hundred or so candidates with platform-specific experience in their region, often offering similar packages.
4. Geography concentrates the talent — and the competition
In Europe, commercial -omics talent clusters around a handful of hubs:
| Region | Concentration |
|---|---|
| DACH (Germany, Switzerland, Austria) | Strong in capital equipment sales, pharma accounts, mass spec |
| UK Golden Triangle (Cambridge, Oxford, London) | Heavy on academic core facilities, single-cell, spatial |
| Benelux | Mix of commercial HQs and regional sales coverage |
| France (Paris, Lyon) | Pharma and clinical genomics focus |
| Nordics (Stockholm, Copenhagen) | Academic and emerging biotech |
In the US, talent concentrates around Boston/Cambridge, the Bay Area, San Diego, and Research Triangle. APAC adds another layer of complexity, with mature markets (Japan, Singapore, Australia) needing very different profiles from high-growth ones (China, South Korea, India).
If you need a Spanish-speaking Field Application Scientist with spatial transcriptomics experience covering Iberia, you might be looking at five people. Three of them already work for your competitor.
5. Top omics candidates are passive — they aren’t job hunting
Top commercial omics talent is almost never actively searching. They are mid stock-vesting, mid-quota, or six months into a new territory. Industry estimates consistently put the active-to-passive candidate ratio at roughly 1:4 — meaning 80% of the people you actually want will never see your job posting.
This makes passive sourcing essential. Posting a job and waiting will surface a small fraction of the real qualified market. The rest must be approached, courted, and convinced — usually over months, not weeks.
6. Compensation benchmarks are moving — and uneven
Salary expectations in commercial omics have shifted significantly since 2021. OTE for senior FAS roles in Europe now regularly exceeds €100K, and Sales Specialist OTE for high-end capital equipment can reach €180–220K. But variance between countries, platforms, and company stage (Series B startup vs. listed multinational) is significant.
Companies that benchmark off generic life-sciences salary surveys consistently underpay — and then lose finalists at the offer stage. For current numbers, see our European biotech commercial salary benchmarks.
7. The omics community is small — employer reputation travels fast
Because the community is small, candidates know each other. They know which manager has a reputation for micromanaging, which company missed its last raise, and which startup’s tech “doesn’t quite work as advertised at the bench.” Glassdoor matters less than direct reference checks through former colleagues.
This puts a real premium on employer brand, transparency in interviewing, and reputation management — areas many emerging biotech companies underinvest in until it costs them a finalist.
What this means for your hiring strategy
If you are recruiting commercial omics talent, the playbook from other industries — post a JD, run applicants through an ATS, hire the best of the inbound — will fail. What works instead:
- Map the market before you open the role. Know which 20–50 people globally could fill the position, where they sit today, and what would move them.
- Hire for trajectory, not just fit today. Top omics commercial talent grows fast; their next role might already be at your competitor.
- Move quickly when you find someone. Top candidates have multiple options. Companies that take six weeks between interview stages lose them.
- Compensate for the real market, not the budget you wrote in Q1. The salary band you set six months ago is probably already behind.
- Invest in your employer story. Why would a Senior FAS at Illumina join your Series B? Make that answer specific and compelling.
How specialist omics recruitment changes the equation
This is why SRC-Search exists. We have spent over a decade building a global network in the commercial omics space — across genomics, single-cell, spatial biology, proteomics, NGS, and adjacent fields. Our team is scientifically trained (PhDs included), so we have substantive conversations with candidates about technology, fit, and trajectory — not just compensation and job titles.
Most of our 700+ placements come from candidates who were not actively looking, but were the right person at the right moment when we reached out. That is what specialist recruitment in this market looks like.
If you are hiring across Europe, the US, or APAC and the usual approaches aren’t working, book a call with our team.
Frequently asked questions
Why is hiring genomics and proteomics talent harder than hiring other biotech roles?
Genomics and proteomics commercial roles require both deep scientific literacy and commercial fluency in the same person. Pure scientists struggle with quota carrying and pricing conversations; pure salespeople cannot credibly discuss assay design, library prep, or data analysis with PhD-level customers. The intersection of the two skill sets is rare, which shrinks the qualified pool to the low thousands globally.
How do I hire biotech talent across Europe?
Effective European biotech hiring requires three things: a region-specific market map (DACH, UK Golden Triangle, Benelux, France, and Nordics each behave differently), salary benchmarks calibrated by country and platform rather than a single European average, and a sourcing approach that targets passive candidates. Posting a job in English and relying on inbound applications will miss the majority of qualified talent. Most successful European hires come from direct outreach to candidates currently employed at competitor companies.
How long does it take to recruit a Field Application Scientist?
A typical Field Application Scientist search in commercial omics takes 8–14 weeks from market map to signed offer, assuming a focused territory and clear platform requirements. Searches that require rare combinations (e.g., specific language + specific platform + specific therapeutic area) can take 4–6 months. Speed depends heavily on how well-mapped the candidate pool is at the start of the search.
What is the difference between a generalist recruiter and a specialist omics recruiter?
A generalist life-sciences recruiter typically works across pharma, medical devices, and biotech tools without deep technical knowledge of specific platforms. A specialist omics recruiter understands the technology stack (NGS, single-cell, spatial, mass spec), the competitive landscape (which companies have which platforms), and the candidate community personally. The practical difference shows up in candidate quality, time-to-fill, and offer acceptance rate.
How much does a bad commercial hire in biotech cost?
A single bad commercial hire in biotech can cost €350,000–€550,000 or more, factoring in salary, missed revenue, replacement cost, and ramp time for the next person. For senior roles or long sales-cycle products, the cost is higher. See our detailed analysis: The True Cost of a Bad Commercial Hire in Biotech.
Should I use an in-house recruiter or an external specialist for omics roles?
In-house recruiters work well for high-volume roles where the company has strong employer brand and a steady candidate flow. External specialists work well for niche, senior, or international roles where the qualified candidate pool is small and mostly passive. Many biotech scale-ups use a hybrid: in-house for support functions, external specialists for commercial and leadership roles in -omics.
